{"id":468969,"date":"2021-03-31T15:44:26","date_gmt":"2021-03-31T19:44:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=468969"},"modified":"2021-03-31T15:44:26","modified_gmt":"2021-03-31T19:44:26","slug":"azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/","title":{"rendered":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, March 31, 2021<\/span> \/PRNewswire\/ — <\/p>\n

\n

\n
\n \"Rosen
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n WHY:\u00a0<\/b>Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca plc (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.<\/p>\n

\n SO WHAT:<\/b>\u00a0If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses.<\/p>\n

\n WHAT TO DO NEXT: <\/b>To join the prospective class action, go to http:\/\/www.rosenlegal.com\/cases-register-2062.html<\/a>\u00a0or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email pkim@rosenlegal.com<\/a> or cases@rosenlegal.com<\/a> for information on the class action.<\/p>\n

\n WHAT IS THIS ABOUT: <\/b>On March 23, 2021<\/span>, National Institute of Allergy and Infectious Diseases (NIAID) released a statement on AstraZenaca’s COVID-19 vaccine information which stated, “[l]ate Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial.” The statement continued, “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”<\/p>\n

On this news, AstraZenaca’s American Depositary Share (ADS) price fell in pre-market trading on March 23, 2021<\/span>, damaging investors.<\/p>\n

\n WHY ROSEN LAW: <\/b>We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013 and has recovered hundreds of millions of dollars for investors.\u00a0 In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020 founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Laurence Rosen, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 Phillip Kim, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0 275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0 New York, NY<\/span> 10016
\u00a0\u00a0\u00a0\u00a0\u00a0 Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0 Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0 Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0 lrosen@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 pkim@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 cases@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 www.rosenlegal.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation–azn-301259962.html<\/a><\/p>\n

SOURCE Rosen Law Firm, P.A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, March 31, 2021 \/PRNewswire\/ — WHY:\u00a0Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca plc (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT:\u00a0If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to http:\/\/www.rosenlegal.com\/cases-register-2062.html\u00a0or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the … <\/p>\n

Continue reading “AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-468969","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, March 31, 2021 \/PRNewswire\/ — WHY:\u00a0Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca plc (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT:\u00a0If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to http:\/\/www.rosenlegal.com\/cases-register-2062.html\u00a0or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the … Continue reading "AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-31T19:44:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN\",\"datePublished\":\"2021-03-31T19:44:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/\"},\"wordCount\":494,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/\",\"name\":\"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"datePublished\":\"2021-03-31T19:44:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/","og_locale":"en_US","og_type":"article","og_title":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk","og_description":"PR Newswire NEW YORK, March 31, 2021 \/PRNewswire\/ — WHY:\u00a0Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AstraZeneca plc (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. SO WHAT:\u00a0If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to http:\/\/www.rosenlegal.com\/cases-register-2062.html\u00a0or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the … Continue reading \"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-31T19:44:26+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN","datePublished":"2021-03-31T19:44:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/"},"wordCount":494,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/","name":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation - AZN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","datePublished":"2021-03-31T19:44:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/azn-breaking-news-rosen-global-investor-counsel-encourages-astrazeneca-plc-investors-to-inquire-about-class-action-investigation-azn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AZN BREAKING NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca plc Investors to Inquire About Class Action Investigation – AZN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=468969"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468969\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=468969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=468969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=468969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}